Pancreatic cancer remains a leading cause of cancer-related death with few available
therapies for advanced disease. Recently, patients with germline BRCA mutations have …

Background Pancreatic cancer (PC) is among foremost causes of cancer related deaths
worldwide due to generic symptoms, lack of effective screening strategies and resistance to …

Extensive desmoplasia is a prominent feature of the pancreatic ductal adenocarcinoma
(PDAC) microenvironment. Initially, studies demonstrated that desmoplasia promotes …

Although pancreatic cancer often invades peripancreatic adipose tissue, little information is
known about cancer‐adipocyte interaction. We first investigated the ability of adipocytes to …

Background Pancreatic ductal adenocarcinoma is the deadliest cancer worldwide with a
98% loss‐of‐life expectancy and a 30% increase in the disability‐adjusted life years during …

Background This open-label, phase I/II study evaluated safety and efficacy for first-line
liposomal irinotecan+ oxaliplatin+ 5-fluorouracil+ leucovorin (NALIRIFOX). Methods Patients …

Pancreatic ductal adenocarcinoma (PDAC) remains a difficult tumor to diagnose and treat.
To date, PDAC lacks routine screening with no markers available for early detection …

Simple Summary Pancreatic cancer has a five-year survival rate of less than 8% and is the
fourth leading cause of cancer death in the United States. Existing therapeutics have failed …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor
prognosis. The lack of early diagnosis and the absence of suitable biomarkers coupled with …

Lack of durable response to cytotoxic chemotherapy is a major contributor to the dismal
outcomes seen in pancreatic ductal adenocarcinoma (PDAC). Extensive tumor desmoplasia …